SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Artursson Per)
 

Search: WFRF:(Artursson Per) > (2020-2024) > High Throughput Scr...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004896naa a2200541 4500
001oai:DiVA.org:uu-485595
003SwePub
008220926s2022 | |||||||||||000 ||eng|
009oai:gup.ub.gu.se/313630
024a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4855952 URI
024a https://doi.org/10.1007/s11095-022-03171-82 DOI
024a https://gup.ub.gu.se/publication/3136302 URI
040 a (SwePub)uud (SwePub)gu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Chen, Eugene C.u Genentech Inc, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA4 aut
2451 0a High Throughput Screening of a Prescription Drug Library for Inhibitors of Organic Cation Transporter 3, OCT3
264 c 2022-01-28
264 1b Springer,c 2022
338 a electronic2 rdacarrier
520 a Introduction The organic cation transporter 3 (OCT3, SLC22A3) is ubiquitously expressed and interacts with a wide array of compounds including endogenous molecules, environmental toxins and prescription drugs. Understudied as a determinant of pharmacokinetics and pharmacodynamics, OCT3 has the potential to be a major determinant of drug absorption and disposition and to be a target for drug-drug interactions (DDIs).Goal The goal of the current study was to identify prescription drug inhibitors of OCT3.Methods We screened a compound library consisting of 2556 prescription drugs, bioactive molecules, and natural products using a high throughput assay in HEK-293 cells stably expressing OCT3.Results We identified 210 compounds that at 20 mu M inhibit 50% or more of OCT3-mediated uptake of 4-Di-1-ASP (2 mu M). Of these, nine were predicted to inhibit the transporter at clinically relevant unbound plasma concentrations. A Structure-Activity Relationship (SAR) model included molecular descriptors that could discriminate between inhibitors and non-inhibitors of OCT3 and was used to identify additional OCT3 inhibitors. Proteomics of human brain microvessels (BMVs) indicated that OCT3 is the highest expressed OCT in the human blood-brain barrier (BBB).Conclusions This study represents the largest screen to identify prescription drug inhibitors of OCT3. Several are sufficiently potent to inhibit the transporter at therapeutic unbound plasma levels, potentially leading to DDIs or off-target pharmacologic effects.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmaceutiska vetenskaper0 (SwePub)301012 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmaceutical Sciences0 (SwePub)301012 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Farmakologi och toxikologi0 (SwePub)301022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Pharmacology and Toxicology0 (SwePub)301022 hsv//eng
653 a Solute carrier superfamily
653 a extraneuronal monoamine transporter
653 a EMT
653 a EMT
653 a extraneuronal monoamine transporter
653 a Solute carrier superfamily
700a Matsson, Pär,d 1978u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi,Institute of Neuroscience and Physiology, Department of Pharmacology4 aut0 (Swepub:gu)xmatsp
700a Azimi, Minau Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA4 aut
700a Zhou, Xujiau Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA4 aut
700a Handin, Niklasu Uppsala universitet,Institutionen för farmaci4 aut0 (Swepub:uu)nikha230
700a Yee, Sook Wahu Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA4 aut
700a Artursson, Peru Uppsala universitet,Institutionen för farmaci,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)perartur
700a Giacomini, Kathleen M.u Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA4 aut
710a Genentech Inc, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USAb Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi4 org
773t Pharmaceutical researchd : Springerg 39:7, s. 1599-1613q 39:7<1599-1613x 0724-8741x 1573-904X
856u https://doi.org/10.1007/s11095-022-03171-8y Fulltext
856u https://uu.diva-portal.org/smash/get/diva2:1699061/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
856u https://link.springer.com/content/pdf/10.1007/s11095-022-03171-8.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-485595
8564 8u https://doi.org/10.1007/s11095-022-03171-8
8564 8u https://gup.ub.gu.se/publication/313630

Find in a library

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view